Tomoyuki Nishida

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Takashi Kadowaki, Joakim Isendahl, Usman Khalid et al. · The Lancet Diabetes & Endocrinology · 2022 · 307 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Julio Rosenstock, Stephen C. Bain, Amoolya Gowda et al. · New England Journal of Medicine · 2023 · 149 citations

Medicine, Pharmacology, Pharmacotherapy +16

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Kohei Kaku, Yuichiro Yamada, Hirotaka Watada et al. · Diabetes Obesity and Metabolism · 2018 · 126 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes

Yutaka Seino, Yasuo Terauchi, Takeshi Osonoi et al. · Diabetes Obesity and Metabolism · 2017 · 121 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

Kohei Kaku, Mads Frederik Rasmussen, Tomoyuki Nishida et al. · Journal of Diabetes Investigation · 2011 · 46 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17